Lucentis Binding Assays
BioOutsource has extensive experience in the development, optimization and qualification of a wide range of different types of binding assays and immunoassays, and offers GLP and cGMP-compliant testing services in compliance with EMA and FDA guidelines to support the biopharmaceutical industry.
Using this experience, we have created a range of off-the-shelf Lucentis (ranibizumab) target-binding assays to support characterization of the high affinity interaction between Lucentis and various isoforms of VEGF.
Early characterisation of the binding of Lucentis(ranibizumab) to VEGF is critical to the long-term success of the product. BioOutsource provides the following VEGF binding assays to support clone selection, process development and comparability studies.
These methods have been developed using different platforms including ELISA, and Surface Plasmon Resonance (SPR) and are performed to provide our partners with full characterization of their Lucentis molecule including affinity, on and off rates as well as relative binding. Comprehensive, industry-leading reports are provided to aid in the understanding of all aspects of your Lucentis (ranibizumab) biosimilar molecule.
BioOutsource offers cost-effective solutions to develop custom methods that are not currently in our portfolio; please contact us to find out more.